Piyush Goyal Champions Biopharma Startups to Propel India's Bioeconomy

On November 5, 2026, Union Minister of Commerce and Industry, Shri Piyush Goyal, convened a pivotal roundtable at Vanijya Bhawan, New Delhi, aimed at strengthening India’s [biopharma](/topic/healthcare-pharma) startup ecosystem. This event, titled "India’s Bioeconomy Opportunity: Role of Startups in Driving Innovation and Growth," was organized by the Department for Promotion of Industry and Internal Trade (DPIIT) in collaboration with NITI Aayog and NITI Frontier Tech Hub. The roundtable gathered key policymakers, industry leaders, and biopharma startups to discuss actionable strategies for positioning India as a global leader in the bioeconomy.

In his address, Goyal emphasized the urgent need to harness India’s scientific capabilities and entrepreneurial talent. He stated, "To become a global leader in the bioeconomy, we must ensure faster approvals, improved access to finance, and stronger collaboration between industry, academia, and government."

Central to the discussions were the proposed regulatory reforms aimed at streamlining the biopharma startup ecosystem. Participants highlighted the necessity for a Regulatory Sandbox, Single Window Clearance, and global regulatory alignment to facilitate quicker market entry for innovative products. Goyal called for time-bound action on the recommendations that emerged from the roundtable, underscoring the importance of a proactive approach to regulatory challenges.

The roundtable also spotlighted the Biopharma SHAKTI initiative, announced in the [Union Budget](/topic/ministry-of-finance) 2026-27, which aims to bolster the biopharma sector through shared infrastructure. This includes the development of laboratories, testing facilities, and clinical trial centers, which are essential for reducing operational costs and enabling startups to scale their innovations effectively.

Debjani Ghosh, Distinguished Fellow at NITI Aayog, stressed the importance of collaboration among startups, industry, academia, and government. She noted, "Building a globally competitive bioeconomy requires a concerted effort from all stakeholders. We must work together to translate scientific discoveries into commercially viable products."

Prof. Gobardhan Das, a member of NITI Aayog, echoed this sentiment, emphasizing the need to strengthen research capabilities. He remarked, "We need to ensure that our scientific advancements are not just theoretical but lead to tangible products that can benefit society."

The roundtable also addressed critical issues surrounding indigenous life sciences manufacturing. Participants discussed measures to expedite customs clearance for laboratory equipment and reagents, which are often bottlenecks for startups. Goyal highlighted the need for stronger inter-ministerial coordination to facilitate coherent policy interventions, stating, "We must ensure that our policies are aligned and that we can resolve sector-specific challenges swiftly."

The discussions also included simplifying access to government schemes and regulatory support, which are crucial for fostering an environment conducive to innovation and growth in the biopharma sector.

As the roundtable concluded, Goyal reiterated the importance of timely implementation of the recommendations discussed. He stated, "The future of India’s bioeconomy depends on our ability to act decisively and collaboratively. We must not only talk about the potential but also take concrete steps to realize it."

This high-level roundtable represents a significant step towards enhancing India’s biopharma startup ecosystem. With a focus on regulatory reforms, infrastructure development, and collaborative efforts, India is poised to accelerate its growth in the bioeconomy sector, potentially positioning itself as a global leader in biopharmaceutical innovation.